Bayer AG
https://www.bayer.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bayer AG
AstraZeneca And Daiichi Eyeing Tumor-Agnostic Future For Enhertu?
The ability of Daiichi-Sankyo/AstraZeneca’s blockbuster antibody-drug conjugate Enhertu to tackle a range of HER2-expressing cancers in a Phase II study could lead to a tumor-agnostic future for the product, new data suggest.
Claritin Liqui-Gels' Label ‘Refresh’ Loses Blue Sky
Changes replace blue background used across Claritin line with white above navy blue waves. Brand’s still printed in white text, but in letters with blue shadow; other package-front text is in red or green instead of yellow.
Japan Nod For Quizartinib In First-Line AML
Japan’s decision gives quizartinib its first approval globally in specific first-line AML indication, in relatively small but high-need patient population.
US Drug Shortages Aid Aurobindo’s Q4 Growth, Decentralized Trials On For Xolair Biosimilar
Drug shortages, stable prices and a demand recovery in the US helped drive Aurobindo’s growth in Q4. Meanwhile, the company is developing a biosimilar to Roche/Novartis’s multi-billion product Xolair, as predicted by Scrip earlier. Use of decentralized mode for its Phase III trials is a notable aspect
Company Information
- Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Radiopharmaceuticals, Contrast Agents
-
Digital Health
- Artificial Intelligence
- Other Names / Subsidiaries
-
- Actus Therapeutics, Inc.
- AskBio
- Asklepios BioPharmaceutical, Inc.
- Synpromics, Ltd.
- RoverMed BioSciences
- NanoCor Therapeutics
- BrainVectis
- Algeta ASA
- Bayer CropScience AG
- Bayer Consumer Care AG
- Berlex Laboratories
- BlueRock Therapeutics
- Conceptus Inc.
- Dihon Pharmaceutical Group Co., Ltd.
- Intendis GmbH
- Jenapharm
- Medrad Inc.
- Possis Medical
- Schering AG
- Monsanto Company
- Zeptosens AG
- KaNDy Therapeutics
- Vividion Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice